A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

428

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy

Interventions

DRUG: Sefaxersen (RO7434656)
DRUG: Placebo

Sponsor

Hoffmann-La Roche